*Univ.Lille, Department of Digestive and Oncological Surgery, Claude Huriez University Hospital, Lille, France†Univ.Lille, URM-S 1172 - JPArc - Centre de Recherche, Jean-Pierre AUBERT Neurosciences et Cancer, Lille, France‡Inserm, UMR-S 1172, Lille, France§Univ.Lille, Department of Pathology, Centre de Biologie et Pathologie, University Hospital, Lille, France¶SIRIC ONCOLille, Lille, France||Univ.Lille, Department of Radiology, Claude Huriez University Hospital, University Hospital, Lille, France**Department of Gastrointestinal Oncology, Oscar Lambret Center, Lille, France††Department of Radiation Oncology, Oscar Lambret Center, Lille, France.
Ann Surg. 2016 Nov;264(5):862-870. doi: 10.1097/SLA.0000000000001769.
To evaluate complete tumor resection rate (primary objective), 30-day postoperative outcomes, and survival (secondary objectives) in patients with a hiatal hernia (HH) ≥5 cm (HH group) compared with those who did not have a HH or presented with a HH <5 cm (control group).
HH is a risk factor for esophageal and junctional adenocarcinoma (EGJA). Its impact on the outcomes after EGJA surgery is unknown.
Among 367 patients who underwent surgery for EGJA, a HH was searched for on computerized tomography scan and barium swallow, with comparison between the HH (n = 42) and control (n = 325) groups.
In the HH group, EGJAs exhibited higher rates of incomplete resection (50.0% vs 4.0%; P < 0.001), of pN3 stages (28.5% vs 10.1%; P = 0.002), and lower median survival (20.9 vs 41.0 mos; P = 0.001). After adjustment, a HH ≥5 cm was a predictor of incomplete resection (odds ratio 21.0, 95% confidence interval 9.4-46.8, P < 0.001) and a poor prognostic factor (hazard ratio 1.6, 95% confidence interval 1.1-2.5, P = 0.025). In the HH group, 30-day mortality was significantly higher in patients who received neoadjuvant radiotherapy (20.0% vs 0%; P = 0.040), which was related to greater cardiac and pulmonary toxicity.
For the first time, we showed that a HH ≥5 cm is associated with a poor prognosis in patients who had surgery for EGJA, linked to greater incomplete resection and lymph node involvement. Neoadjuvant radiotherapy was associated with a significant toxicity in patients with a HH ≥5 cm.
评估疝囊直径≥5cm(HH 组)与无疝或疝囊直径<5cm(对照组)的患者完全肿瘤切除率(主要目标)、30 天术后结果和生存率(次要目标)。
HH 是食管和胃交界处腺癌(EGJA)的危险因素。其对 EGJA 手术后结果的影响尚不清楚。
在 367 例接受 EGJA 手术的患者中,通过计算机断层扫描和钡餐检查寻找 HH,并对 HH(n=42)和对照组(n=325)进行比较。
在 HH 组中,EGJA 的不完全切除率(50.0%比 4.0%;P<0.001)、pN3 期(28.5%比 10.1%;P=0.002)和中位生存时间(20.9 比 41.0 个月;P=0.001)更高。调整后,HH≥5cm 是不完全切除的预测因素(比值比 21.0,95%置信区间 9.4-46.8,P<0.001)和不良预后因素(风险比 1.6,95%置信区间 1.1-2.5,P=0.025)。在 HH 组中,接受新辅助放疗的患者 30 天死亡率显著更高(20.0%比 0%;P=0.040),这与更大的心脏和肺部毒性有关。
我们首次表明,疝囊直径≥5cm 与接受 EGJA 手术的患者预后不良相关,与不完全切除和淋巴结受累有关。新辅助放疗与 HH≥5cm 的患者显著毒性相关。